[8-K] NeuroBo Pharmaceuticals, Inc. Common Stock Reports Material Event

Rhea-AI Filing Summary

On July 7, 2025, Helius Medical Technologies, Inc. (NASDAQ: HSDT) received formal notice from The Nasdaq Stock Market LLC confirming that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million. The company had already restored compliance with the minimum bid-price rule 5550(a)(2) on June 3, 2025. As a result, Helius now meets all criteria necessary to maintain its listing on the Nasdaq Capital Market.

Under Nasdaq Listing Rule 5815(d)(4)(B), HSDT will be subject to a Mandatory Panel Monitor until July 7, 2026. If the company falls out of equity compliance during this one-year period, it will receive an immediate delist determination without the usual cure period, although it may request a new hearing.

No additional financial results, transactions, or operational updates were provided in this Form 8-K.

Positive

• Regained compliance with Nasdaq’s $2.5 million stockholders’ equity requirement, securing continued listing
• Previously restored compliance with minimum bid-price rule, fully meeting Nasdaq Capital Market standards

Negative

• Company placed under one-year Mandatory Panel Monitor; any future equity shortfall will prompt immediate delisting proceedings
• Filing does not disclose the exact stockholders’ equity figure, limiting visibility into compliance buffer

Insights

Financial Analyst

TL;DR: Listing compliance restored; delisting risk deferred but one-year probation increases vigilance.

Helius’s confirmation of equity compliance removes an immediate overhang that threatened liquidity and institutional ownership constraints. Regaining both the equity and bid-price standards keeps the shares tradable on Nasdaq, a net positive for market perception and access to capital. However, the Mandatory Panel Monitor until July 2026 means any dip below the $2.5 million equity threshold will trigger a delist determination with no grace period, underscoring the company’s limited margin for error. Investors should monitor forthcoming balance-sheet disclosures to ensure equity remains comfortably above the floor. Overall impact is positive, but sustainability of compliance remains a key risk factor.

0001638287false00016382872025-07-092025-07-09

​​UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549​FORM 8-K​CURRENT REPORT​Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934​Date of Report (Date of earliest event reported): July 9, 2025METAVIA INC.(Exact name of Registrant as Specified in Its Charter)​

​	​	​	​	​
Delaware	​	001-37809	​	47-2389984
(State or other jurisdictionof incorporation)	​	(CommissionFile Number)	​	(IRS EmployerIdentification No.)

​​

​​​	​
545 Concord Avenue, Suite 210Cambridge, Massachusetts ​	​	02138
(Address of principal executive offices)	​	(Zip Code)

​(857) 702-9600(Registrant’s telephone number, including area code)​Not applicable(Former name or former address, if changed since last report)​Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​Securities registered pursuant to Section 12(b) of the Act:​

​	​	​​	​	​
Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MTVA		The Nasdaq Stock Market LLC

​Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). ​Emerging growth company ☐​If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐​​​​​​

Item 7.01.Regulation FD Disclosures.​On July 9, 2025, MetaVia Inc. (the “Company”) issued a press release announcing that the dosing of the first patient in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Top-line data is expected in the fourth quarter of 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (the "Report"). ​Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.​The information in this Report, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.​Forward-Looking Statements ​Exhibit 99.1 attached hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.​Item 9.01.Financial Statements and Exhibits.​(d) Exhibits​

​	​	​
Exhibit Number		Exhibit Description
99.1	​	Press Release dated July 9, 2025.
104	​	Cover Page Interactive Data File (embedded within Inline XBRL document).

​​​​​​​

​​​​

SIGNATURES​Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.​

​	​	​	​
​		METAVIA INC.
​	​	​
​	​	​
Date: July 9, 2025	​	By:	/s/ Hyung Heon Kim
​	​	​	Hyung Heon Kim
​	​	​	President and Chief Executive Officer

​​​

FAQ

What did Helius Medical Technologies (HSDT) announce on July 7, 2025?

The company received confirmation from Nasdaq that it has regained compliance with the $2.5 million stockholders’ equity requirement.

Which Nasdaq rules has HSDT now satisfied?

It meets Listing Rule 5550(b)(1) for equity and had previously met Rule 5550(a)(2) for minimum bid price.

How long will HSDT be monitored by Nasdaq?

The company will be under a Mandatory Panel Monitor until July 7, 2026.

What happens if HSDT falls below the equity requirement during the monitor period?

Nasdaq will issue an immediate delist determination letter without a cure period, though HSDT can request a hearing.

Does this 8-K include any earnings or financial results?

No. The filing only addresses Nasdaq listing compliance; no earnings or other financial data were provided.